JP2019517790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517790A5 JP2019517790A5 JP2018559282A JP2018559282A JP2019517790A5 JP 2019517790 A5 JP2019517790 A5 JP 2019517790A5 JP 2018559282 A JP2018559282 A JP 2018559282A JP 2018559282 A JP2018559282 A JP 2018559282A JP 2019517790 A5 JP2019517790 A5 JP 2019517790A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- chain domain
- nucleic acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 108020004707 nucleic acids Proteins 0.000 claims 29
- 102000039446 nucleic acids Human genes 0.000 claims 29
- 150000007523 nucleic acids Chemical class 0.000 claims 29
- 210000004027 cell Anatomy 0.000 claims 18
- 108091008874 T cell receptors Proteins 0.000 claims 14
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 14
- 239000013598 vector Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000012642 immune effector Substances 0.000 claims 8
- 229940121354 immunomodulator Drugs 0.000 claims 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 6
- 230000037431 insertion Effects 0.000 claims 5
- 238000003780 insertion Methods 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 2
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 claims 2
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 claims 2
- 201000005027 Lynch syndrome Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000037433 frameshift Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1608052.5 | 2016-05-09 | ||
| GBGB1608052.5A GB201608052D0 (en) | 2016-05-09 | 2016-05-09 | T-cell receptors which recognise frameshift mutants of TGF-beta RII |
| PCT/EP2017/061087 WO2017194555A1 (en) | 2016-05-09 | 2017-05-09 | T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517790A JP2019517790A (ja) | 2019-06-27 |
| JP2019517790A5 true JP2019517790A5 (enExample) | 2020-06-18 |
Family
ID=56297359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559282A Pending JP2019517790A (ja) | 2016-05-09 | 2017-05-09 | ＴＧＦβＲＩＩのフレームシフト変異体を認識するＴ細胞受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190336529A1 (enExample) |
| EP (1) | EP3455249B1 (enExample) |
| JP (1) | JP2019517790A (enExample) |
| KR (1) | KR20190016507A (enExample) |
| CN (1) | CN109328196B (enExample) |
| AU (1) | AU2017261684A1 (enExample) |
| CA (1) | CA3024555A1 (enExample) |
| EA (1) | EA201892217A1 (enExample) |
| GB (1) | GB201608052D0 (enExample) |
| IL (1) | IL262873A (enExample) |
| MX (1) | MX2018013581A (enExample) |
| SG (1) | SG11201809716VA (enExample) |
| WO (1) | WO2017194555A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10724043B2 (en) * | 2016-10-06 | 2020-07-28 | Nantbio, Inc. | Multi-pulse transfection methods and cells |
| US20190358263A1 (en) | 2016-12-07 | 2019-11-28 | Oslo Universitetssykehus Hf | Compositions and Methods for Cell Therapy |
| GB201713078D0 (en) | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
| WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
| WO2020057619A1 (zh) * | 2018-09-21 | 2020-03-26 | 广东香雪精准医疗技术有限公司 | 一种识别afp抗原的高亲和力t细胞受体 |
| WO2020201527A1 (en) * | 2019-04-04 | 2020-10-08 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
| GB201907663D0 (en) | 2019-05-30 | 2019-07-17 | Ab Mavatar | Method for diagnosing colorectal cancer |
| WO2022072760A1 (en) * | 2020-10-02 | 2022-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| WO2023050063A1 (zh) * | 2021-09-28 | 2023-04-06 | 溧阳瑅赛生物医药有限公司 | 一种识别hla-a*02:01/e629-38的tcr及其应用 |
| US20260070960A1 (en) | 2022-09-01 | 2026-03-12 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
| WO2024263818A2 (en) * | 2023-06-20 | 2024-12-26 | Immunova Therapeutics Llc | Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains |
| CN121532421A (zh) * | 2023-06-21 | 2026-02-13 | 北京可瑞生物科技有限公司 | 经修饰的tcr恒定区及其在tcr融合蛋白中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| FR2779432A1 (fr) * | 1998-06-08 | 1999-12-03 | Transgene Sa | Sequence nucleique du recepteur rii du tgfb, peptide code, et utilisations |
| BR112012001977A2 (pt) * | 2009-07-29 | 2017-01-31 | Glaxo Group Ltd | domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar. |
| EP3954704A1 (en) * | 2011-06-03 | 2022-02-16 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
| WO2014088432A1 (en) * | 2012-12-06 | 2014-06-12 | Callaghan Innovation Research Limited | Conjugate compounds |
| WO2015169853A1 (en) * | 2014-05-06 | 2015-11-12 | Universitetet I Oslo | Engineered invariant chain molecule for improved mhc class i loading |
| WO2015189267A2 (en) * | 2014-06-10 | 2015-12-17 | Universitetet I Oslo | Engineered invariant chain molecule for improved mhc class i loading |
-
2016
- 2016-05-09 GB GBGB1608052.5A patent/GB201608052D0/en not_active Ceased
-
2017
- 2017-05-09 WO PCT/EP2017/061087 patent/WO2017194555A1/en not_active Ceased
- 2017-05-09 SG SG11201809716VA patent/SG11201809716VA/en unknown
- 2017-05-09 CA CA3024555A patent/CA3024555A1/en active Pending
- 2017-05-09 KR KR1020187035676A patent/KR20190016507A/ko not_active Abandoned
- 2017-05-09 CN CN201780038176.8A patent/CN109328196B/zh active Active
- 2017-05-09 US US16/099,329 patent/US20190336529A1/en not_active Abandoned
- 2017-05-09 EA EA201892217A patent/EA201892217A1/ru unknown
- 2017-05-09 AU AU2017261684A patent/AU2017261684A1/en not_active Abandoned
- 2017-05-09 MX MX2018013581A patent/MX2018013581A/es unknown
- 2017-05-09 JP JP2018559282A patent/JP2019517790A/ja active Pending
- 2017-05-09 EP EP17725537.9A patent/EP3455249B1/en active Active
-
2018
- 2018-11-07 IL IL262873A patent/IL262873A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517790A5 (enExample) | ||
| TWI710572B (zh) | 改善配對的ｔ細胞受體 | |
| BR112018070741A2 (pt) | receptor de células t (tcr), tcr que se liga a um complexo hla-a*02, molécula de fusão a anti-cd3 de tcr, ácido nucleico, vetor de expressão, célula, célula de ocorrência não natural e/ou purificada e/ou projetada, composição farmacêutica, método de tratamento de um indivíduo humano em necessidade deste, formulação injetável para administração a um indivíduo humano, e método de produção de um tcr | |
| JP2017537627A5 (enExample) | ||
| JP2017501130A5 (enExample) | ||
| JP2019511222A5 (enExample) | ||
| MX2023003463A (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. | |
| JP2017501129A5 (enExample) | ||
| JP2018509163A5 (enExample) | ||
| MX2022015821A (es) | Nuevos receptores de celulas t y usos de los mismos. | |
| JP2019500894A5 (enExample) | ||
| CA3045233A1 (en) | Novel t cell receptors and immune therapy using the same | |
| BR112019027291A2 (pt) | receptores de células t, molécula de fusão anti-cd3 de tcr, ácido nucleico, vetor de expressão, célula, composição farmacêutica, método de tratar um sujeito humano que tem câncer, formulação injetável para administrar a um sujeito humano e método de produzir um tcr | |
| MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| RU2016124179A (ru) | СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека | |
| JP2020500523A5 (enExample) | ||
| JP2016505635A5 (enExample) | ||
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| NZ739448A (en) | Transgene genetic tags and methods of use | |
| FI3430030T3 (fi) | Transfektoituja t-soluja ja t-solureseptoreita käytettäviksi syöpien immunoterapiassa | |
| EA201892217A1 (ru) | Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII | |
| JP2014500724A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| JP2017006120A5 (enExample) | ||
| MX2023013078A (es) | Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos. |